– CANADA, Mississauga – Cipher Pharmaceuticals Inc. (TSX: CPH) today announced that following the meeting of its Annual and Special Meeting of Shareholders held on June 11, 2019, Craig Mull was appointed as the new Chairman of the board of directors.
“Cipher is grateful to Mark Beaudet and Dr. Laurence Terrisse-Rulleau, the outgoing directors, for their service to the Board and wish them continued success in their professional endeavors,” said Craig Mull, Chairman of the Board.
About Cipher Pharmaceuticals Inc.
Cipher is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. Cipher is focused on a three-pronged growth strategy – including acquisitions, in-licensing, and selective investments in drug development – to assemble a broad portfolio of prescription products that serve unmet medical needs.
For more information: https://www.cipherpharma.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.